Oxytocin and carbetocin are both uterotonic agents used for prevention and treatment of postpartum hemorrhage (PPH), the leading cause of maternal mortality worldwide. Oxytocin is the natural neuropeptide and current first-line agent; carbetocin is a synthetic analogue with extended duration designed for single-dose PPH prevention. Understanding their pharmacological differences informs rational uterotonic selection.
Molecular Profiles
Section titled “Molecular Profiles”Oxytocin
Section titled “Oxytocin”Oxytocin is a 9-amino acid cyclic neuropeptide produced by the hypothalamus and released from the posterior pituitary:
- Sequence: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ (disulfide bridge: Cys¹–Cys⁶)
- Molecular weight: ~1,007 Da
- Receptor: Oxytocin receptor (OXTR) — Gq-coupled
- Half-life: 3–5 minutes (IV); 10–15 minutes (IM)
- Source: Endogenous; synthetic (Pitocin)
Carbetocin
Section titled “Carbetocin”Carbetocin is a synthetic oxytocin analogue with modifications at positions 1 and 4:
- Sequence: 1-Mpa-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ (disulfide bridge: Mpa¹–Cys⁶; 4-deamino)
- Molecular weight: ~988 Da
- Receptor: OXTR (agonist) with some vasopressin V1a activity
- Half-life: ~30–40 minutes (IV); ~45–60 minutes (IM)
- Source: Synthetic (Péristat, Heat)
The key structural modifications are:
- Position 1: Cysteine → Mercaptopropionic acid (Mpa) — removes the free amino group, conferring resistance to aminopeptidase degradation.
- Position 4: Asparagine → Deaminated asparagine — further enhances metabolic stability.
These modifications extend the half-life 6–10× beyond native oxytocin without altering uterotonic potency.
Receptor Pharmacology
Section titled “Receptor Pharmacology”| Property | Oxytocin | Carbetocin |
|---|---|---|
| OXTR affinity | High | High (comparable) |
| V1a receptor activity | Minimal | Moderate |
| V2 receptor activity | Minimal | Minimal |
| Uterotonic potency | 1× (reference) | ~1× (comparable) |
| Receptor selectivity | OXTR-selective | OXTR + V1a |
Carbetocin’s additional V1a receptor activity produces mild vasoconstriction, which may contribute to its hemostatic effect but also explains its slightly different side effect profile.
Pharmacokinetic Comparison
Section titled “Pharmacokinetic Comparison”| Parameter | Oxytocin (IV) | Oxytocin (IM) | Carbetocin (IV) |
|---|---|---|---|
| Onset | 1–3 minutes | 5–10 minutes | 2–3 minutes |
| Peak effect | 5–10 minutes | 15–30 minutes | 5–15 minutes |
| Duration | 30–60 minutes | 1–3 hours | 2–4 hours |
| Dosing interval | Continuous infusion | Every 15–30 min | Single dose |
| Half-life | 3–5 min | 10–15 min | 30–40 min |
The fundamental pharmacokinetic difference is that oxytocin requires continuous IV infusion to maintain uterotonic effect, while carbetocin’s extended half-life allows a single bolus dose for sustained uterine contraction.
Clinical Evidence
Section titled “Clinical Evidence”Oxytocin
Section titled “Oxytocin”Oxytocin has the most extensive evidence base of any uterotonic:
- Active Management of Third Stage of Labor (AMTSL): Oxytocin 10 IU IM after delivery reduces PPH risk by 60% compared to expectant management.
- WHO recommendation: First-line agent for PPH prevention (10 IU IM) and treatment (30 IU in 500 mL IV infusion).
- Efficacy: Reduces blood loss >500 mL by 50–60% when used in AMTSL.
Carbetocin
Section titled “Carbetocin”Carbetocin’s evidence base is growing, particularly in low-resource settings:
- COMPPASS trial (2018): Carbetocin 100 µg IV was non-inferior to oxytocin 10 IU IV for prevention of PPH (blood loss ≥500 mL) in a double-blind randomized trial (N=29,780).
- Heat-stable carbetocin (2023): WHO prequalification of heat-stable formulation for use in settings without cold chain — a major advancement for resource-limited environments.
- Comparison with misoprostol: Carbetocin showed superior PPH prevention compared to misoprostol (oral) in head-to-head trials.
Comparative Efficacy
Section titled “Comparative Efficacy”| Outcome | Oxytocin | Carbetocin |
|---|---|---|
| PPH prevention (≥500 mL) | 60% reduction | Non-inferior to oxytocin |
| Blood loss ≥1000 mL | ~70% reduction | ~70% reduction |
| Uterine atony treatment | Effective (IV) | Less effective (prophylactic) |
| Need for additional uterotonic | 10–15% | 8–12% |
| Surgical intervention | 1–2% | 1–2% |
Dosing and Administration
Section titled “Dosing and Administration”| Parameter | Oxytocin | Carbetocin |
|---|---|---|
| Prophylactic dose | 10 IU IM | 100 µg IV |
| Treatment dose | 30 IU in 500 mL IV | 100 µg IV (repeat) |
| Route (prophylaxis) | IM preferred | IV preferred |
| Route (treatment) | IV infusion | IV bolus |
| Cold chain required | Yes (2–8°C) | No (heat-stable form) |
| Stability | 24 hours at room temp | 36 months at 25°C (heat-stable) |
The heat-stable carbetocin formulation represents a paradigm shift for low-resource settings where cold chain infrastructure is unavailable. The WHO’s 2023 prequalification of this formulation recommends it as an alternative to oxytocin in such settings.
Side Effects
Section titled “Side Effects”| Effect | Oxytocin | Carbetocin |
|---|---|---|
| Nausea/vomiting | 10–15% | 10–15% |
| Abdominal cramping | 10–15% | 10–15% |
| Hypotension | 5–10% (IV) | 3–5% |
| Tachycardia | 5–10% | 5–10% |
| Water intoxication | Rare (high-dose IV) | Very rare |
| Flushing | 5–10% | 5–10% |
| Headache | 5–10% | 5–10% |
Carbetocin’s side effect profile is broadly similar to oxytocin, with the absence of significant water intoxication risk — a concern with high-dose oxytocin IV infusion.
Special Populations
Section titled “Special Populations”Hypertensive Disorders
Section titled “Hypertensive Disorders”| Consideration | Oxytocin | Carbetocin |
|---|---|---|
| Vasopressin V1a activity | None | Moderate |
| Blood pressure effect | Mild pressor | Mild-moderate pressor |
| Pre-eclampsia | Generally safe | Use with caution |
| Recommendation | First-line | Second-line |
Carbetocin’s V1a activity produces mild vasoconstriction that may be clinically relevant in patients with hypertensive disorders of pregnancy. Oxytocin is preferred in this population.
Cesarean Section
Section titled “Cesarean Section”| Consideration | Oxytocin | Carbetocin |
|---|---|---|
| Evidence | Extensive | Growing |
| Dose (prophylaxis) | 5 IU IV | 100 µg IV |
| Efficacy | Well-established | Non-inferior |
| Recommendation | First-line | Alternative |
Both agents are effective for uterine atony prevention during cesarean delivery, with oxytocin remaining the first-line choice due to its extensive evidence base.
Summary
Section titled “Summary”Oxytocin and carbetocin are both effective uterotonic agents with complementary pharmacological profiles. Oxytocin remains the global first-line agent for PPH prevention due to its extensive evidence base, low cost, and established efficacy across all clinical scenarios. Carbetocin’s extended half-life (30–40 minutes vs. 3–5 minutes) enables single-dose prophylaxis without continuous infusion — a significant advantage in resource-limited settings. The 2023 WHO prequalification of heat-stable carbetocin eliminates cold chain requirements, making it a transformative option for low-resource environments. The choice between them depends on clinical setting (resource availability, cold chain), patient factors (hypertensive disorders), and the distinction between prophylaxis (both effective) and treatment of active hemorrhage (oxytocin preferred).